Effectiveness of omalizumab in chronic spontaneous urticaria assessed with patient-reported outcomes: a prospective study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Effectiveness of omalizumab in chronic spontaneous urticaria assessed with patient-reported outcomes : a prospective study. / Ghazanfar, M. N.; Holm, J. G.; Thomsen, S. F.

I: Journal of the European Academy of Dermatology and Venereology. Supplement, Bind 32, Nr. 10, 10.2018, s. 1761-1767.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Ghazanfar, MN, Holm, JG & Thomsen, SF 2018, 'Effectiveness of omalizumab in chronic spontaneous urticaria assessed with patient-reported outcomes: a prospective study', Journal of the European Academy of Dermatology and Venereology. Supplement, bind 32, nr. 10, s. 1761-1767. https://doi.org/10.1111/jdv.15045

APA

Ghazanfar, M. N., Holm, J. G., & Thomsen, S. F. (2018). Effectiveness of omalizumab in chronic spontaneous urticaria assessed with patient-reported outcomes: a prospective study. Journal of the European Academy of Dermatology and Venereology. Supplement, 32(10), 1761-1767. https://doi.org/10.1111/jdv.15045

Vancouver

Ghazanfar MN, Holm JG, Thomsen SF. Effectiveness of omalizumab in chronic spontaneous urticaria assessed with patient-reported outcomes: a prospective study. Journal of the European Academy of Dermatology and Venereology. Supplement. 2018 okt;32(10):1761-1767. https://doi.org/10.1111/jdv.15045

Author

Ghazanfar, M. N. ; Holm, J. G. ; Thomsen, S. F. / Effectiveness of omalizumab in chronic spontaneous urticaria assessed with patient-reported outcomes : a prospective study. I: Journal of the European Academy of Dermatology and Venereology. Supplement. 2018 ; Bind 32, Nr. 10. s. 1761-1767.

Bibtex

@article{d5870814279b49ca97e03bb6e47ae936,
title = "Effectiveness of omalizumab in chronic spontaneous urticaria assessed with patient-reported outcomes: a prospective study",
abstract = "Aim: To examine the effectiveness of omalizumab (anti-IgE) on symptoms and disease-related quality of life in chronic spontaneous urticaria (CSU) and to identify possible patient-specific factors associated with response to omalizumab in patients with antihistamine refractory CSU. Methods: Six months prospective trial of omalizumab 300 mg every 4 weeks among patients with CSU from a dermatological university department. The primary outcome was the urticaria activity score in the past week (UAS7) at 3 months. Results: A total of 117 patients (39 men and 78 women) with a mean age of 42 years were included. The mean baseline UAS7 score was 29.3 points (SD = 10.8), which improved to 11.9 points (SD = 12.9) at 3 months follow-up, difference = 17.4 points (95{\%} CI: 14.8–19.9), P < 0.0001. Other patient-reported outcomes (PROs) also improved significantly during 3 months of treatment. No significant further improvement was seen between three and 6 months follow-up. None of the following patient-specific factors: sex, age, age of onset of CSU, symptom duration, presence of chronic inducible urticaria (CINDU), comorbidities, positive urticaria HR test, smoking, ethnicity, angio-oedema, serum total IgE level, CRP, leucocytes, absolute neutrophil count or previous treatment with prednisolone or montelukast were significantly associated with response to omalizumab at 3 months, P > 0.05 for all comparisons. Previous treatment with traditional immunosuppressant drugs (azathioprine, cyclosporine or methotrexate) was associated with poorer treatment response to omalizumab at 3 months, P < 0.001. A strong correlation was seen between different patient-reported outcomes (PROs) at baseline and 3 months follow-up. Fifteen patients (12.8{\%}) reported side-effects of the treatment. Conclusion: Omalizumab is a highly effective therapy for antihistamine refractory CSU with treatment effects similar to those observed in randomized controlled trials. Validated PROs to assess disease activity, disease control and impairment of quality of life are valuable tools in the clinical management of CSU. Identification of patient-specific predictors of effect and safety of omalizumab in CSU is still warranted.",
author = "Ghazanfar, {M. N.} and Holm, {J. G.} and Thomsen, {S. F.}",
year = "2018",
month = "10",
doi = "10.1111/jdv.15045",
language = "English",
volume = "32",
pages = "1761--1767",
journal = "Journal of the European Academy of Dermatology and Venereology. Supplement",
issn = "0929-0168",
publisher = "Wiley-Blackwell",
number = "10",

}

RIS

TY - JOUR

T1 - Effectiveness of omalizumab in chronic spontaneous urticaria assessed with patient-reported outcomes

T2 - a prospective study

AU - Ghazanfar, M. N.

AU - Holm, J. G.

AU - Thomsen, S. F.

PY - 2018/10

Y1 - 2018/10

N2 - Aim: To examine the effectiveness of omalizumab (anti-IgE) on symptoms and disease-related quality of life in chronic spontaneous urticaria (CSU) and to identify possible patient-specific factors associated with response to omalizumab in patients with antihistamine refractory CSU. Methods: Six months prospective trial of omalizumab 300 mg every 4 weeks among patients with CSU from a dermatological university department. The primary outcome was the urticaria activity score in the past week (UAS7) at 3 months. Results: A total of 117 patients (39 men and 78 women) with a mean age of 42 years were included. The mean baseline UAS7 score was 29.3 points (SD = 10.8), which improved to 11.9 points (SD = 12.9) at 3 months follow-up, difference = 17.4 points (95% CI: 14.8–19.9), P < 0.0001. Other patient-reported outcomes (PROs) also improved significantly during 3 months of treatment. No significant further improvement was seen between three and 6 months follow-up. None of the following patient-specific factors: sex, age, age of onset of CSU, symptom duration, presence of chronic inducible urticaria (CINDU), comorbidities, positive urticaria HR test, smoking, ethnicity, angio-oedema, serum total IgE level, CRP, leucocytes, absolute neutrophil count or previous treatment with prednisolone or montelukast were significantly associated with response to omalizumab at 3 months, P > 0.05 for all comparisons. Previous treatment with traditional immunosuppressant drugs (azathioprine, cyclosporine or methotrexate) was associated with poorer treatment response to omalizumab at 3 months, P < 0.001. A strong correlation was seen between different patient-reported outcomes (PROs) at baseline and 3 months follow-up. Fifteen patients (12.8%) reported side-effects of the treatment. Conclusion: Omalizumab is a highly effective therapy for antihistamine refractory CSU with treatment effects similar to those observed in randomized controlled trials. Validated PROs to assess disease activity, disease control and impairment of quality of life are valuable tools in the clinical management of CSU. Identification of patient-specific predictors of effect and safety of omalizumab in CSU is still warranted.

AB - Aim: To examine the effectiveness of omalizumab (anti-IgE) on symptoms and disease-related quality of life in chronic spontaneous urticaria (CSU) and to identify possible patient-specific factors associated with response to omalizumab in patients with antihistamine refractory CSU. Methods: Six months prospective trial of omalizumab 300 mg every 4 weeks among patients with CSU from a dermatological university department. The primary outcome was the urticaria activity score in the past week (UAS7) at 3 months. Results: A total of 117 patients (39 men and 78 women) with a mean age of 42 years were included. The mean baseline UAS7 score was 29.3 points (SD = 10.8), which improved to 11.9 points (SD = 12.9) at 3 months follow-up, difference = 17.4 points (95% CI: 14.8–19.9), P < 0.0001. Other patient-reported outcomes (PROs) also improved significantly during 3 months of treatment. No significant further improvement was seen between three and 6 months follow-up. None of the following patient-specific factors: sex, age, age of onset of CSU, symptom duration, presence of chronic inducible urticaria (CINDU), comorbidities, positive urticaria HR test, smoking, ethnicity, angio-oedema, serum total IgE level, CRP, leucocytes, absolute neutrophil count or previous treatment with prednisolone or montelukast were significantly associated with response to omalizumab at 3 months, P > 0.05 for all comparisons. Previous treatment with traditional immunosuppressant drugs (azathioprine, cyclosporine or methotrexate) was associated with poorer treatment response to omalizumab at 3 months, P < 0.001. A strong correlation was seen between different patient-reported outcomes (PROs) at baseline and 3 months follow-up. Fifteen patients (12.8%) reported side-effects of the treatment. Conclusion: Omalizumab is a highly effective therapy for antihistamine refractory CSU with treatment effects similar to those observed in randomized controlled trials. Validated PROs to assess disease activity, disease control and impairment of quality of life are valuable tools in the clinical management of CSU. Identification of patient-specific predictors of effect and safety of omalizumab in CSU is still warranted.

U2 - 10.1111/jdv.15045

DO - 10.1111/jdv.15045

M3 - Journal article

VL - 32

SP - 1761

EP - 1767

JO - Journal of the European Academy of Dermatology and Venereology. Supplement

JF - Journal of the European Academy of Dermatology and Venereology. Supplement

SN - 0929-0168

IS - 10

ER -

ID: 210014218